Still, our present study suggests significant benefits of STVNA treatment, specifically in reducing IL-6 and GM-CSF expression at the cellular level, using our in vitro model of stroke, which signals the need for further investigation, by including, for instance, permeability assays. Here, IL6 is linked to stroke disorder.